how many people take glp-1 drugs Just Americans are taking GLP-1s now Beyond Weight Loss: 59% of

A.XieG.Almeida PereiraT.BoursierJ.BohnicB.et al (2015)

Of those people, some experienced side effects not observed in clinical trials, specifically body temperature and hormonal/menstrual disruptions

et al (2016) Arabidopsis CBL interacting protein kinase 3 interacts with ABR1, an APETALA2 domain transcription factor, to regulate ABA responses

Some observers have opined that the European agency is stricter than the US Food and Drug Administration, which has not yet addressed this issue

Cardiovascular outcome trials in patients with T2D have demonstrated the efficacy of GLP-1 RAs in reducing major adverse cardiovascular events, including cardiovascular death, MI and stroke, regardless of glycaemic control